The Streptavidin coated AlphaPlex™ 645 (Samarium) Acceptor beads are used to capture a wide variety of biotinylated reagents, ranging from small nucleotides to very large proteins. To avoid steric hindrance, it is recommended to use biotin derivatives including an aliphatic spacer composed of at least six carbons.
false falseFor research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).
The Streptavidin coated AlphaPlex™ 645 (Samarium) Acceptor beads are used to capture a wide variety of biotinylated reagents, ranging from small nucleotides to very large proteins. To avoid steric hindrance, it is recommended to use biotin derivatives including an aliphatic spacer composed of at least six carbons. These beads can be used in conjunction with Alpha Donor beads to create no-wash assays for:
AlphaPlex Acceptor beads are intended to be used in multiplexing assays, in conjunction with AlphaLISA Acceptor beads and Alpha Donor beads. In a typical Alpha assay, 1 mg of Acceptor beads is sufficient to run 1,000-2,000 wells using a 50 μL reaction volume.
| 抗體偶聯物 | Streptavidin |
|---|---|
| 自動化兼容 | Yes |
| 珠型或核心珠型 | AlphaPlex Samarium (645) Acceptor |
| 檢測方法 | Alpha |
| 實驗類型 | In vitro |
| Format | Microplates |
| 產品品牌名稱 | AlphaPlex |
| 包裝量 | 1.0 per pack |
| 運輸條件 | 藍冰 |
| 產品尺寸 | 250 µg |
Technical advancements in antibody engineering has brought about greater interest in more novel antibody therapeutic design and the emergence of new classes of antibody therapeutics called bispecific antibodies (bsAbs). The principle behind bispecific antibody design is to create an antibody / an ...
Anti-inflammatory monoclonal antibody drugs that specifically target TNFα, such as Humira®, have been highly successful in the market. As patents expire on these top-selling drugs, effort has been placed on developing biosimilars. Biosimilars differ from small molecule generi ...
The introduction of enzyme-linked immunosorbent assays (ELISAs) in the early 1970’s offered researchers a non-radiometric immunoassay platform without compromising sensitivity. Over the last 50 years scientists have made huge strides in disease research and drug discovery and a demand for greater ...
